Macquarie Group
PRAX icon

Macquarie Group’s Praxis Precision Medicines PRAX Stock Holding History

Macquarie Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-966
Closed -$59 – 2069
2024
Q1 		$59 Buy
+966
New +$43.3K ﹤0.01% 1647
2022
Q4 		– Sell
-83
Closed -$3K – 2032
2022
Q3 		$3K Hold
83
– – ﹤0.01% 2487
2022
Q2 		$3K Hold
83
– – ﹤0.01% 2552
2022
Q1 		$13 Hold
83
– – ﹤0.01% 2481
2021
Q4 		$24K Hold
83
– – ﹤0.01% 2355
2021
Q3 		$23K Buy
+83
New +$22.5K ﹤0.01% 2427

Other funds holding PRAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Macquarie Group's PRAX Position: Q2 2024 in Review

Macquarie Group sold out of Praxis Precision Medicines (PRAX) in Q2 2024, closing a stake of 966 shares — an estimated $59 sold.

Macquarie Group first reported a position in PRAX in Q3 2021 and held it in 6 quarters. The position peaked at $24K in Q4 2021. 113 funds tracked by Wall St. Rank hold PRAX as of Q2 2024.

  • Macquarie Group reported no remaining Praxis Precision Medicines position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 966 Praxis Precision Medicines shares in Q2 2024, an estimated $59.
  • Macquarie Group first reported a position in Praxis Precision Medicines in Q3 2021 and held it in 6 quarters.
  • Macquarie Group's Praxis Precision Medicines position peaked at $24K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.